Poor efficacy of Trametinib and other MEK inhibitors in pancreatic cancer is caused by a reciprocal increase or maintenance in alternate signalling activity, such as the AKT/mTOR pathway activity45. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.